EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials

Syed Muhammad Muneeb Akhtar iD, Abraish Ali iD, Muhammad Sohaib Khan iD, Vareesha Khan iD, Areeba Fareed iD, Syed Zia Saleem iD, Munazza Mumtaz iD, Muhammad Nadeem Ahsan, Sadia Iqbal, Muhammad Sohaib Asghar iD

International Journal of Gynecology & Obstetrics · 2024

DOI: 10.1002/ijgo.15467 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift International Journal of Gynecology & Obstetrics, 2024. Verfasst von Syed Muhammad Muneeb Akhtar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan. Hauptthemen laut MEDLINE: Hot Flashes, Postmenopause. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vasomotor symptoms (VMS), such as hot flashes and night sweats, are highly prevalent and burdensome for women experiencing menopausal transition. Fezolinetant, a selective neurokinin 3 receptor (NK3R) antagonist, is a potential therapeutic option for mitigating VMS.

Objectives

Our aim is to assess the efficacy and evaluate the safety profile of fezolinetant compared with placebo in post‐menopausal women suffering from VMS, by pooling all the relevant data and reflecting the most current evidence. Search Strategy/Selection Criteria An extensive literature search was performed in the PubMed, Medline and Cochrane Library databases from inception until June 2023 to identify relevant trials. Data Collection and Analysis Mean differences (MDs) and 95% confidence intervals (CIs) were calculated for continuous outcomes. Risk ratios (RRs) were calculated for dichotomous outcomes. All statistical analyses were performed using R Statistical Software. Main Results A total of six randomized controlled trials were added. For the frequency of daily VMS, the combined pooled result favored the fezolinetant group over placebo (MD –2.38, 95% CI –2.64 to −2.12; P < 0.001, I 2 = 0%). For the severity of daily VMS, fezolinetant was again found to be superior to the placebo group (MD –0.40, 95% CI –0.51 to −0.29; P < 0.001, I 2 = 70%). Fezolinetant (120 mg) consistently demonstrated a significant reduction in the severity of daily moderate/severe VMS compared with other doses at both 4 and 12 weeks. Patient‐reported outcomes (PROs) of Greene Climacteric Scale (GCS), PROMIS the Sleep Disturbance Short Form 8b and Menopause‐Specific Quality of Life (MENQoL) scores indicated significant improvement with fezolinetant. No significant difference in efficacy of fezolinetant at 4 and 12 weeks were observed in any outcome. As for safety, no significant differences in the treatment emergent adverse events at 12 weeks were found between fezolinetant and placebo.

Conclusions

Our study significantly favors fezolinetant over placebo regarding the primary efficacy outcomes of daily moderate to severe VMS frequency and severity, including PROs, while both the groups are comparable in terms of treatment emergent adverse events. Further studies are needed to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hot FlashesPostmenopauseFemaleHumansMiddle AgedCycloheptanesHeterocyclic Compounds, 2-RingQuality of LifeRandomized Controlled Trials as TopicSweatingThiadiazolesTreatment OutcomeVasomotor System

Stichwörter der Autor:innen

NK3R antagonistsfezolinetantmeta‐analysispostmenopausal womenvasomotor symptoms

Substanzen

CycloheptanesfezolinetantHeterocyclic Compounds, 2-RingThiadiazoles

Autor:innen und Institutionen

  • Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan.
  • Department of Obstetrics and Gynecology, Civil Hospital, Karachi, Pakistan.
  • Department of Nephrology, Dow University of Health Sciences, Karachi, Pakistan.
  • Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Syed Muhammad Muneeb Akhtar, Abraish Ali, Muhammad Sohaib Khan, Vareesha Khan, Areeba Fareed, Syed Zia Saleem, Munazza Mumtaz, Muhammad Sohaib Asghar

Zitieren

APA

Akhtar, S. M. M., Ali, A., Khan, M. S., Khan, V., Fareed, A., Saleem, S. Z., Mumtaz, M., Ahsan, M. N., Iqbal, S., & Asghar, M. S. (2024). Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15467

Vancouver

Akhtar SMM, Ali A, Khan MS, Khan V, Fareed A, Saleem SZ, et al. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials. International Journal of Gynecology & Obstetrics. 2024. doi:10.1002/ijgo.15467

BibTeX
@article{Akhtar2024,
  author = {Akhtar, Syed Muhammad Muneeb and Ali, Abraish and Khan, Muhammad Sohaib and Khan, Vareesha and Fareed, Areeba and Saleem, Syed Zia and Mumtaz, Munazza and Ahsan, Muhammad Nadeem and Iqbal, Sadia and Asghar, Muhammad Sohaib},
  title = {Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2024},
  doi = {10.1002/ijgo.15467}
}
Kostenlos starten →